A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
收藏DataCite Commons2025-12-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008419/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in
patients with non-metastatic castration-resistant prostate cancer.
提供机构：
Vivli
创建时间：
2022-09-02
